News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|November 8, 2021

Technological Addictions: The New Frontier in Addiction Psychiatry

Author(s)Petros Levounis, MD, MA

Addiction to technology: what concerns should you have as a clinician?

Petros Levounis, MD, MA, discusses the wake-up call the medical community needs concerning technological addictions, the subject of his new book: Technological Addictions.

Do you have patients who are addicted to technology? Tell us more at PTEditor@mmhgroup.com.

Dr Levounis is professor and chair of the Department of Psychiatry at Rutgers New Jersey Medical School; chief of service at University Hospital in Newark, New Jersey; and the author of 13+ books.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Innovative Sciences: Eric Nestler, MD, PhD Reflects on Research and Leadership in Medicine

ByEric J. Nestler, MD, PhD

January 21st 2026

opioids substance use disorder

Precision Medicine for Opioid Use Disorder: Insights From New Review

ByPoorvanshi Alag, MD,Jessica Walters

January 19th 2026

substance use disorder adhd

Do ADHD Stimulant Medications Have an Effect on Substance Use?

ByJessica Walters

January 18th 2026

pain

A Network-Based Approach to Depression, Neuropathic Pain, and Substance Use Disorder Using Coadministered TMS and Ketamine

BySteven R. Devore Best, MD

January 15th 2026

naloxone nasal spray

Patent Issued for Rezenopy, the Highest Dosage Naloxone Nasal Spray Approved by the FDA

January 14th 2026

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

sNDA Submission: Igalmi for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia in Outpatient Setting

Mental Health Grants Cut Then Restored in 24 Hours: Leading Organizations React to Environment of Uncertainty

New ADHD Medications Discussed at APSARD 2026

Violence in Psychiatry: Stop Pretending It’s Just “Part of the Job”

Muscarinic Cholinergic Circuitry in Schizophrenia: Our Evolving Understanding